Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7508814 | Drug and Alcohol Dependence | 2011 | 9 Pages |
Abstract
Rifampin is a more potent inducer of buprenorphine metabolism than rifabutin with pharmacokinetic and pharmacodynamic adverse consequences. Those patients requiring rifampin treatment for tuberculosis and receiving buprenorphine therapy are likely to require an increase in buprenorphine dose to prevent withdrawal symptoms. Rifabutin administration was associated with decreases in buprenorphine plasma concentrations, but no clinically significant adverse events were observed.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Elinore F. McCance-Katz, David E. Moody, Sudha Prathikanti, Gerald Friedland, Petrie M. Rainey,